Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for acute pulmonary embolism
ACTRN12625001164482Phase 2Recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Nov 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liraglutide in pulmonary embolism (PE) (2 arms), sponsored by Western Sydney Local Health District. Primary endpoint: Change in biomarkers of vascular inflammation. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on ACTRN12625001164482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001164482.